NEWS: Chimeron Bio Welcomes Kevin Heyeck as New CEO

NEWS: Chimeron Bio Appoints Antonin (Tony) de Fougerolles to its Board of Directors

Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.

Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics and vaccines to bring more effective gene therapies and personalized medicines to patients.

Explore Our Pipeline

How we do it

Our ChaESAR Platform

Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.

Learn How

Why we do it

Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs

We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.

About the Science Explore Our Pipeline

rna cancer infectious disease rare genetic disorders
curve seperator

The Latest from Chimeron Bio

in the news

In the News

December 15, 2022

Chimeron Bio Appoints Antonin (Tony) de Fougerolles to its Board of Directors 

Philadelphia, PA – December 15, 2022 – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors. As the former founding CSO of Moderna, Tony is […]

From Our Blog

July 1, 2020

My Science, My Strongest Tool for Social Justice

The pharma and biotech community can help address not only unmet health needs, but also health inequities. Our role as scientists is critical right now.

passionate about science

Learn more about our COVID-19 Vaccine Program.

See what makes ChaESAR™ a robust anti-viral approach.

Read the Press Release